Ocular Therapeutix Inc
NASDAQ:OCUL

Watchlist Manager
Ocular Therapeutix Inc Logo
Ocular Therapeutix Inc
NASDAQ:OCUL
Watchlist
Price: 8.83 USD 3.64% Market Closed
Market Cap: 1.4B USD
Have any thoughts about
Ocular Therapeutix Inc?
Write Note

Intrinsic Value

OCUL's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

The intrinsic value of one OCUL stock under the Base Case scenario is 2.8 USD. Compared to the current market price of 8.83 USD, Ocular Therapeutix Inc is Overvalued by 68%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

OCUL Intrinsic Value
2.8 USD
Overvaluation 68%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Ocular Therapeutix Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for OCUL cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about OCUL?
Bearish
Neutral
Bullish

Fundamental Analysis

Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Investment Journal
AI Assistant
AI Assistant
Ask me anything about Ocular Therapeutix Inc

Provide an overview of the primary business activities
of Ocular Therapeutix Inc.

What unique competitive advantages
does Ocular Therapeutix Inc hold over its rivals?

What risks and challenges
does Ocular Therapeutix Inc face in the near future?

Has there been any significant insider trading activity
in Ocular Therapeutix Inc recently?

Summarize the latest earnings call
of Ocular Therapeutix Inc.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Ocular Therapeutix Inc.

Provide P/S
for Ocular Therapeutix Inc.

Provide P/E
for Ocular Therapeutix Inc.

Provide P/OCF
for Ocular Therapeutix Inc.

Provide P/FCFE
for Ocular Therapeutix Inc.

Provide P/B
for Ocular Therapeutix Inc.

Provide EV/S
for Ocular Therapeutix Inc.

Provide EV/GP
for Ocular Therapeutix Inc.

Provide EV/EBITDA
for Ocular Therapeutix Inc.

Provide EV/EBIT
for Ocular Therapeutix Inc.

Provide EV/OCF
for Ocular Therapeutix Inc.

Provide EV/FCFF
for Ocular Therapeutix Inc.

Provide EV/IC
for Ocular Therapeutix Inc.

Show me price targets
for Ocular Therapeutix Inc made by professional analysts.

What are the Revenue projections
for Ocular Therapeutix Inc?

How accurate were the past Revenue estimates
for Ocular Therapeutix Inc?

What are the Net Income projections
for Ocular Therapeutix Inc?

How accurate were the past Net Income estimates
for Ocular Therapeutix Inc?

What are the EPS projections
for Ocular Therapeutix Inc?

How accurate were the past EPS estimates
for Ocular Therapeutix Inc?

What are the EBIT projections
for Ocular Therapeutix Inc?

How accurate were the past EBIT estimates
for Ocular Therapeutix Inc?

Compare the revenue forecasts
for Ocular Therapeutix Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Ocular Therapeutix Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Ocular Therapeutix Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Ocular Therapeutix Inc compared to its peers.

Compare the P/E ratios
of Ocular Therapeutix Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Ocular Therapeutix Inc with its peers.

Analyze the financial leverage
of Ocular Therapeutix Inc compared to its main competitors.

Show all profitability ratios
for Ocular Therapeutix Inc.

Provide ROE
for Ocular Therapeutix Inc.

Provide ROA
for Ocular Therapeutix Inc.

Provide ROIC
for Ocular Therapeutix Inc.

Provide ROCE
for Ocular Therapeutix Inc.

Provide Gross Margin
for Ocular Therapeutix Inc.

Provide Operating Margin
for Ocular Therapeutix Inc.

Provide Net Margin
for Ocular Therapeutix Inc.

Provide FCF Margin
for Ocular Therapeutix Inc.

Show all solvency ratios
for Ocular Therapeutix Inc.

Provide D/E Ratio
for Ocular Therapeutix Inc.

Provide D/A Ratio
for Ocular Therapeutix Inc.

Provide Interest Coverage Ratio
for Ocular Therapeutix Inc.

Provide Altman Z-Score Ratio
for Ocular Therapeutix Inc.

Provide Quick Ratio
for Ocular Therapeutix Inc.

Provide Current Ratio
for Ocular Therapeutix Inc.

Provide Cash Ratio
for Ocular Therapeutix Inc.

What is the historical Revenue growth
over the last 5 years for Ocular Therapeutix Inc?

What is the historical Net Income growth
over the last 5 years for Ocular Therapeutix Inc?

What is the current Free Cash Flow
of Ocular Therapeutix Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for Ocular Therapeutix Inc.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Ocular Therapeutix Inc

Current Assets 473m
Cash & Short-Term Investments 427.2m
Receivables 30.2m
Other Current Assets 15.6m
Non-Current Assets 17.4m
PP&E 15.7m
Other Non-Current Assets 1.6m
Current Liabilities 36.4m
Accounts Payable 4m
Accrued Liabilities 32.2m
Other Current Liabilities 190k
Non-Current Liabilities 102m
Long-Term Debt 67.8m
Other Non-Current Liabilities 34.2m
Efficiency

Earnings Waterfall
Ocular Therapeutix Inc

Revenue
61.4m USD
Cost of Revenue
-5.8m USD
Gross Profit
55.7m USD
Operating Expenses
-196.9m USD
Operating Income
-141.3m USD
Other Expenses
-33.1m USD
Net Income
-174.3m USD

Free Cash Flow Analysis
Ocular Therapeutix Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

OCUL Profitability Score
Profitability Due Diligence

Ocular Therapeutix Inc's profitability score is 27/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
ROE is Increasing
Positive 3-Years Revenue Growth
Positive Revenue Growth Forecast
27/100
Profitability
Score

Ocular Therapeutix Inc's profitability score is 27/100. The higher the profitability score, the more profitable the company is.

OCUL Solvency Score
Solvency Due Diligence

Ocular Therapeutix Inc's solvency score is 64/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Negative Net Debt
Long-Term Solvency
Low D/E
64/100
Solvency
Score

Ocular Therapeutix Inc's solvency score is 64/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

OCUL Price Targets Summary
Ocular Therapeutix Inc

Wall Street analysts forecast OCUL stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for OCUL is 18.59 USD with a low forecast of 14.14 USD and a high forecast of 23.1 USD.

Lowest
Price Target
14.14 USD
60% Upside
Average
Price Target
18.59 USD
110% Upside
Highest
Price Target
23.1 USD
162% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for OCUL?

Click here to dive deeper.

Dividends

Ocular Therapeutix Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for OCUL is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Ownership

OCUL Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Profile

Ocular Therapeutix Inc Logo
Ocular Therapeutix Inc

Country

United States of America

Industry

Pharmaceuticals

Market Cap

1.4B USD

Dividend Yield

0%

Description

Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. The company is headquartered in Bedford, Massachusetts and currently employs 228 full-time employees. The company went IPO on 2014-07-25. The Company’s product pipeline candidates provide differentiated drug delivery solutions. The Company’s products include dexamethasone insert (DEXTENZA) and ReSure Sealant. Its DEXTENZA is an intracanalicular insert for the treatment of post-surgical ocular inflammation and pain. Its ReSure Sealant is an ophthalmic device designed to prevent wound leaks in corneal incisions following cataract surgery. The Company’s products that are in pipeline include OTX-TKI for the treatment of wet AMD, OTX-TIC for the treatment of glaucoma and ocular hypertension, OTX-CSI for the chronic treatment of dry eye disease, and OTX-DED for the short-term treatment of the signs and symptoms of dry eye disease.

Contact

MASSACHUSETTS
Bedford
24 Crosby Dr
+17818953235.0
www.ocutx.com

IPO

2014-07-25

Employees

228

Officers

CFO, COO & Principal Accounting Officer
Mr. Donald Notman Jr.
Chief Scientific Officer
Dr. Jeffrey S. Heier M.D.
Executive Chairman, President & CEO
Dr. Pravin U. Dugel M.D.
Chief Technology Officer
Dr. Peter K. Jarrett Ph.D.
Vice President of Investor Relations
Mr. William S. Slattery Jr.
Chief Legal Officer & Corporate Secretary
Mr. Todd D.C. Anderman
Show More
Vice President of Global Sales & Marketing
Mr. William H. Ransone II
Vice President of Human Resources
Ms. Tracy Smith
Chief Commercial Officer
Mr. Steve Meyers
Chief Development Officer
Dr. Peter K. Kaiser M.D.
Show Less

See Also

Discover More
What is the Intrinsic Value of one OCUL stock?

The intrinsic value of one OCUL stock under the Base Case scenario is 2.8 USD.

Is OCUL stock undervalued or overvalued?

Compared to the current market price of 8.83 USD, Ocular Therapeutix Inc is Overvalued by 68%.

Back to Top